VolitionRx Demonstrates Early-Stage Cancer Detection Breakthrough at ESMO MAP
Event summary
- VolitionRx presented early-stage I solid cancer detection data at the ESMO MAP Conference on September 10, 2026.
- Capture-Seq™ technology detected 49/49 cancers in the first cohort, including 23 early-stage I/II cancers, with no false positives.
- Blinded validation cohort of 81 subjects showed 95% detection rate for stage I and II cancers.
- VolitionRx is fast-tracking development, including studies on competing conditions and collaborations with oncology key opinion leaders.
The big picture
VolitionRx's presentation at ESMO MAP underscores the growing importance of liquid biopsy technologies in early cancer detection. The $36 billion TAM for early cancer detection and minimal residual disease (MRD) monitoring highlights the strategic significance of this breakthrough. If validated, Capture-Seq™ could reshape the competitive landscape for multi-cancer early detection tests, positioning VolitionRx as a key player in precision oncology.
What we're watching
- Validation Pace
- The pace at which VolitionRx can validate Capture-Seq™ in larger, more diverse cohorts will determine its clinical adoption.
- Competitive Positioning
- Whether VolitionRx can sustain its lead in circulating cell-free nucleoproteins against emerging liquid biopsy technologies.
- Regulatory Pathway
- How quickly VolitionRx can navigate regulatory approvals for its multi-cancer early detection (MCED) approach.
Related topics